Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

ARNA 6.35 +0.20 (3.25%)
price chart
What Arena's Belviq Television Ad Campaign Means For The Stock
The weight loss drug Belviq from Arena Pharmaceuticals (ARNA) is now being promoted on television with a national advertising campaign.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): The Future Is Encouraging
That being the case, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) seems to have come to the realization that unless it takes proactive steps to expand the market share of its anti-obesity drug Belviq, it might as well miss out on a great opportunity.
Stocks Alert: Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Medical Marijuana ...
Lakeway, NY - (MARKET NEWS CALL) - 4/14/2014� Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S.
Related articles »  
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Expecting Sales to hit $150M this ...
Dallas, Texas 03/31/2014 (ustradevoice) - Biopharmaceutical Company, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), expects majority of its revenue for the year to come from its flagship drug, Belviq.
Coverage of Biotech Equities -- Research on Arena Pharma, Celgene, PDL ...
Free technical research on ARNA, CELG, PDLI and HEB can be downloaded upon signing up at: http://www.investor-edge.com/905-register On Monday, shares in Arena Pharmaceuticals Inc. gained 2.57% to close the day at $6.38. The stock recorded a ...
Related articles »  
Arena Pharmaceuticals, Inc. (ARNA) news: Direct-To-Consumer Television ...
Arena (ARNA) and its marketing partner Eisai (OTCPK:ESALY) recently announced a major new stage in commercialization strategy and promotional mix that I believe could be the tipping point for a significant upward inflection in BELVIQ sales.
Arena - Belviq Sales Up Modestly Heading Into Television Ads
It is certainly an interesting time to be an investor in Arena Pharmaceuticals (ARNA). The company is about 10 months into its launch of the anti-obesity drug Belviq and the equity has taken several lumps along the way.
Arena Pharmaceuticals, Inc. (ARNA) news: Arena Down With Overall Market ...
As we head toward the end of the first quarter, and the fiscal year end for Arena's (ARNA) marketing partner Eisai (OTCPK:ESALY), it is appropriate to assess where we are for both companies in terms of the sales for the anti-obesity drug Belviq.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Plans For A Bright Tomorrow
Dallas, Texas 03/19/2014 (ustradevoice) - Arena Pharmaceuticals Inc. (NASDAQ:ARNA) has been in the news lately for introducing the new drug BELVIQ.
To Play Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Patience Is Needed  WallStreetPR
Related articles »  
Arena Pharmaceuticals Sees Large Decrease in Short Interest (ARNA)
Arena Pharmaceuticals (NASDAQ:ARNA) last announced its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the analysts' consensus estimate of $0.02 by $0.13. The company had ...
Related articles »